Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BEVERLY J LONG

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1932497245
CMS profile
1340862
Location
SARASOTA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$13.18

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $13.18 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Stryker Corporation $13.18 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BEVERLY J LONG

NPI 1932497245 · CMS profile ID 1340862

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

SARASOTA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932497245?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BEVERLY J LONG, NPI 1932497245, CMS profile ID 1340862. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932497245?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BEVERLY J LONG, NPI 1932497245, CMS profile ID 1340862. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932497245?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BEVERLY J LONG, NPI 1932497245, CMS profile ID 1340862, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1932497245?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $13.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Stryker Corporation $13.1807/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 806582308 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,793.03 10
PY2021 $13.18 1
PY2022 $605.11 4
PY2025 $342.01 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $330,018.58 24
PY2024 Principal investigator $323,036.19 11
PY2023 Principal investigator $560,143.33 30
PY2022 Principal investigator $257,964.83 9
PY2021 Principal investigator $417,708.03 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $2,249.45 12/31/2025 Covered Recipient Teaching Hospital
Sarasota Memorial Hospital
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT-ov65 No dispute reported 06/30/2026 1232927433
Principal investigator 1 Merck Sharp & Dohme LLC $23,650.01 12/31/2025 Covered Recipient Teaching Hospital
Sarasota Memorial Hospital
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient dMMR Advanced or Recurrent Endometrial Carcinoma in the First-line Setting K No dispute reported 06/30/2026 1232928632
Principal investigator 1 ABBVIE INC. $6,420.33 12/16/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202420974
Principal investigator 1 Genmab U.S., Inc. $27,000.00 11/20/2025 Non-covered Recipient Entity
SARASOTA MEMORIAL HEALTH CARE SYSTEM
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235934610
Principal investigator 1 ABBVIE INC. $600.00 11/12/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202420966
Principal investigator 1 ABBVIE INC. $7,758.40 10/15/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202420962
Principal investigator 1 ABBVIE INC. $13,877.60 10/02/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202420958
Principal investigator 1 Genmab U.S., Inc. $1,000.00 09/10/2025 Non-covered Recipient Entity
SARASOTA MEMORIAL HEALTH CARE SYSTEM
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235934607
Principal investigator 1 ABBVIE INC. $600.00 09/03/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202420948
Principal investigator 1 ABBVIE INC. $1,000.00 09/03/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202420950
Principal investigator 1 ABBVIE INC. $11,175.60 09/03/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202420955
Principal investigator 1 Merck Sharp & Dohme LLC $16,605.12 08/31/2025 Covered Recipient Teaching Hospital
Sarasota Memorial Hospital
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT-ov65 No dispute reported 06/30/2026 1232927477
Principal investigator 1 Merck Sharp & Dohme LLC $66,420.80 08/31/2025 Covered Recipient Teaching Hospital
Sarasota Memorial Hospital
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient dMMR Advanced or Recurrent Endometrial Carcinoma in the First-line Setting K No dispute reported 06/30/2026 1232928634
Principal investigator 1 Genmab U.S., Inc. $15,421.90 08/27/2025 Non-covered Recipient Entity
SARASOTA MEMORIAL HEALTH CARE SYSTEM
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235934601
Principal investigator 1 Genmab U.S., Inc. $1,000.00 08/27/2025 Non-covered Recipient Entity
SARASOTA MEMORIAL HEALTH CARE SYSTEM
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235934604
Principal investigator 1 ABBVIE INC. $14,980.77 07/17/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202420944
Principal investigator 1 ABBVIE INC. $23,500.00 07/09/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine No dispute reported 06/30/2026 1202420939
Principal investigator 1 Merck Sharp & Dohme LLC $88,358.60 06/23/2025 Covered Recipient Teaching Hospital
Sarasota Memorial Hospital
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT-ov65 No dispute reported 06/30/2026 1232927431
Principal investigator 1 ABBVIE INC. $750.00 04/14/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202420911
Principal investigator 1 ABBVIE INC. $1,500.00 04/14/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202420916
Principal investigator 1 ABBVIE INC. $600.00 04/14/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202420919
Principal investigator 1 ABBVIE INC. $750.00 04/14/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202420921
Principal investigator 1 ABBVIE INC. $4,500.00 03/04/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202420878
Principal investigator 1 ABBVIE INC. $300.00 02/06/2025 Covered Recipient Teaching Hospital
SARASOTA MEMORIAL HOSPITAL
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202420874